ES2064887T3 - Composiciones quimicas solidas estabilizadas. - Google Patents

Composiciones quimicas solidas estabilizadas.

Info

Publication number
ES2064887T3
ES2064887T3 ES91202070T ES91202070T ES2064887T3 ES 2064887 T3 ES2064887 T3 ES 2064887T3 ES 91202070 T ES91202070 T ES 91202070T ES 91202070 T ES91202070 T ES 91202070T ES 2064887 T3 ES2064887 T3 ES 2064887T3
Authority
ES
Spain
Prior art keywords
water soluble
alkaline stabilizer
chemical compositions
solid chemical
stabilized solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91202070T
Other languages
English (en)
Inventor
Haan Pieter De
Der Ven Cornelus Josephus Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of ES2064887T3 publication Critical patent/ES2064887T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds

Abstract

SE PRESENTAN COMPOSICIONES QUIMICAS (EJ. FARMACEUTICAS) DESHIDRATADAS ESTABILIZADAS QUE CONTIENEN UNA SAL DE ADICION ACIDA DISOLUBLE EN AGUA DE UN COMPUESTO BASICO POCO SOLUBLE (EJ. MIANSERINA, APOMORFINA, CLOROPROMAZINA, IMIPRAMINA O PROMETAZINA); UN EXCIPIENTE SELECCIONADO DEL GRUPO QUE CONSISTE EN CELULOSA MICROCRISTALINA, LACTOSA, FOSFATO DE HIDROGENO CALCICO Y MEZCLAS DEL MISMO; Y UN ESTABILIZADOR ALCALINO DISOLUBLE EN AGUA (> 2 MG/ML). LA COMPOSICION DESHIDRATADA ES RELATIVAMENTE MAS ESTABLE QUE UNA QUE NO CONTIENE EL ESTABILIZADOR ALCALINO DISOLUBLE EN AGUA, ESPECIALMENTE DESPUES DE UN PROCESO DE GRANULACION A ALTA TEMPERATURA. EL PROCESO PARA LA PREPARACION DE LA COMPOSICION DESHIDRATADA ES TAMBIEN MAS "VIGOROSO" CON EL ESTABILIZADOR ALCALINO DISOLUBLE EN AGUA AÑADIDO.
ES91202070T 1990-09-13 1991-08-13 Composiciones quimicas solidas estabilizadas. Expired - Lifetime ES2064887T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58185990A 1990-09-13 1990-09-13

Publications (1)

Publication Number Publication Date
ES2064887T3 true ES2064887T3 (es) 1995-02-01

Family

ID=24326864

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91202070T Expired - Lifetime ES2064887T3 (es) 1990-09-13 1991-08-13 Composiciones quimicas solidas estabilizadas.

Country Status (14)

Country Link
EP (1) EP0475482B1 (es)
JP (1) JP3153577B2 (es)
KR (1) KR100196209B1 (es)
AT (1) ATE112491T1 (es)
AU (1) AU643920B2 (es)
CA (1) CA2049811C (es)
DE (1) DE69104453T2 (es)
DK (1) DK0475482T3 (es)
ES (1) ES2064887T3 (es)
FI (1) FI104361B (es)
IE (1) IE65274B1 (es)
NZ (1) NZ239753A (es)
PT (1) PT98955B (es)
ZA (1) ZA916661B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2194867T3 (es) * 1993-03-26 2003-12-01 Franciscus Wilhelmus He Merkus Composiciones farmaceuticas para la administracion intranasal de apomorfina.
CA2284719A1 (en) * 1997-03-26 1998-10-01 Franciscus W.H.M. Merkus Nasal melatonin composition
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
US6691057B2 (en) 2001-02-26 2004-02-10 L.U.M. Gesellschaft Fur Labor- Umweltdiagnostic & Medizintechnik Mbh Method and device for accelerated stability analysis
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
CA2491665A1 (fr) * 2004-12-24 2006-06-24 Louis Cartilier Formulation de comprime pour liberation soutenue de principe actif
MX2008014024A (es) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
WO2010072776A1 (en) 2008-12-23 2010-07-01 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
CN102753161A (zh) 2009-11-27 2012-10-24 贝林格尔.英格海姆国际有限公司 基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
CN106975074A (zh) 2010-06-24 2017-07-25 勃林格殷格翰国际有限公司 糖尿病治疗
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
WO2013010964A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
RU2609198C1 (ru) * 2016-01-25 2017-01-30 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма имипрамина немедленного высвобождения и способ ее получения
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina
KR102416406B1 (ko) * 2019-09-24 2022-07-04 주식회사 종근당 티카그렐러의 산 부가염을 포함하는 안정화된 약학 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2554736A (en) 1951-05-29 Tertiary aminoalkyl-iminodibenzyls
US2018410A (en) 1933-12-11 1935-10-22 Victor Chemical Works Dentifrice preparation
US2287699A (en) 1940-02-15 1942-06-23 Monsanto Chemicals Stabilized dicalcium phosphate
US3012852A (en) 1956-06-06 1961-12-12 Monsanto Chemicals Stabilized calcium phosphates and process therefor
DE1277222B (de) 1965-12-22 1968-09-12 Knapsack Ag Verfahren zur Stabilisierung von Dicalciumphosphatdihydrat
NL129434C (es) 1966-03-12
US4128641A (en) 1975-07-31 1978-12-05 Hzi Research Center Inc. Tetracyclic psychotropic drug
DE2648061C2 (de) 1976-10-23 1982-11-04 Hoechst Ag, 6000 Frankfurt Verfahren zum Stabilisieren von Di-calciumhydrogenphosphatdihydrat
DE2741513A1 (de) 1977-09-15 1979-03-22 Benckiser Gmbh Joh A Verfahren zum stabilisieren von calciumhydrogenphosphat-dihydrat gegen hydrolyse
CA1183328A (en) 1980-12-12 1985-03-05 Thomas W. Gerard Compacting calcium phosphate
SE8103843L (sv) * 1981-06-18 1982-12-19 Astra Laekemedel Ab Farmaceutisk mixtur
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US5004651A (en) 1989-01-24 1991-04-02 Abbott Laboratories Stabilizing system for solid dosage forms
GB8920693D0 (en) * 1989-09-13 1989-10-25 Nicholas Kiwi Pty Ltd Non-effervescent ibuprofen compositions

Also Published As

Publication number Publication date
DE69104453D1 (de) 1994-11-10
KR100196209B1 (ko) 1999-06-15
PT98955B (pt) 1999-02-26
EP0475482B1 (en) 1994-10-05
ATE112491T1 (de) 1994-10-15
ZA916661B (en) 1992-06-24
DK0475482T3 (da) 1995-04-03
IE913054A1 (en) 1992-02-25
FI104361B (fi) 2000-01-14
AU8341691A (en) 1992-03-19
FI914147A (fi) 1992-03-14
FI914147A0 (fi) 1991-09-03
DE69104453T2 (de) 1995-03-16
KR920005978A (ko) 1992-04-27
JPH0578236A (ja) 1993-03-30
IE65274B1 (en) 1995-10-18
PT98955A (pt) 1992-08-31
CA2049811A1 (en) 1992-03-14
JP3153577B2 (ja) 2001-04-09
CA2049811C (en) 2002-11-05
EP0475482A1 (en) 1992-03-18
NZ239753A (en) 1992-10-28
AU643920B2 (en) 1993-11-25

Similar Documents

Publication Publication Date Title
ES2064887T3 (es) Composiciones quimicas solidas estabilizadas.
KR0136279B1 (ko) 일정수분을 함유하는 서방형 제제
NO176203C (no) Fremgangsmåte for fremstilling av ibuprofentabletter med forsinket frigjöring
US5350582A (en) Stable formulation of enalapril salt, a process for the preparation thereof and the use thereof
ES483767A1 (es) Procedimiento para producir n-arilsulfonil-l-argininamidas
KR910002670B1 (ko) 아모술랄롤 하이드로클로라이드 지속성 제제의 제조방법
US4906647A (en) Stabilized pharmaceutical compositions
MD1007C2 (ro) 1,3-Oxatiolan,izomeri geometrici şi optici ai lui,amestecurile acestor izomeri, procedeu de obţinere a lor şi compoziţie farmaceutică care manifestă activitate antivirotică
MX9706062A (es) FORMAS DE DOSIFICACION ORAL CONTENIENDO UN ANTIBIOTICO DE beta -LACTAMA.
AU751575B2 (en) Pharmaceutical levothyroxine preparation
BR9609964A (pt) Formulação sólida estável de sal de enalaprila e processo para preparação da mesma
JPS5581596A (en) Composition for determining creatine kinase
NO177484C (no) Fremgangsmåte for fremstilling av et farmasöytisk preparat i form av myke kapsler
CA1070299A (en) Stabilized solid form choline salicylate compositions
NO931671L (no) Depot-preparat
KR850008280A (ko) 니페디핀 제제물의 제조방법
ES450520A1 (es) Procedimiento para la obtencion de soluciones solubilizablesy estabilizadas de 2-cloro-11-(4-metil-i-piperazinil)-dibenz(b,f) (1,4) oxazepina.
JPS565412A (en) Pharmaceutical composition
ATE26271T1 (de) Benzhydrylpiperazine-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
JPS55122713A (en) Tablet comprising antibacterial substance
SE8202254L (sv) 2,4-dioxacyklohexanon-derivat
TH6020B (th) สูตรผสมเมนาไดโอนไบซัลโฟท์ที่ได้ทำให้เสถียร และการเตรียมสูตรผสมเหล่านี้
JPS5547643A (en) Complex of optically active alanine-nucleus-substituted mandelic acid and its preparation
TH5974EX (th) สูตรผสมเมนาไดโอนไบซัลโฟท์ที่ได้ทำให้เสถียร และการเตรียมสูตรผสมเหล่านี้
TH8987EX (th) สารผสมโซเดียม เพอร์คาร์บอเนท ที่ปลอดภัย

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 475482

Country of ref document: ES